Department of Statistics, Federal University of Ouro Preto, Brazil.
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.
Stat Med. 2020 Feb 10;39(3):340-351. doi: 10.1002/sim.8405. Epub 2019 Nov 25.
Sequential analysis is used in clinical trials and postmarket drug safety surveillance to prospectively monitor efficacy and safety to quickly detect benefits and problems, while taking the multiple testing of repeated analyses into account. When there are multiple outcomes, each one may be given a weight corresponding to its severity. This paper introduces an exact sequential analysis procedure for multiple weighted binomial end points; the analysis incorporates a drug's combined benefit and safety profile. It works with a variety of alpha spending functions for continuous, group, or mixed group-continuous sequential analysis. The binomial probabilities may vary over time and do not need to be known a priori. The new method was implemented in the free R Sequential package for both one- and two-tailed sequential analysis. An example is given examining myocardial infarction and major bleeding events in patients who initiated non-steroidal antiinflammatory drugs.
序贯分析用于临床试验和上市后药物安全性监测中,以前瞻性监测疗效和安全性,以便快速发现获益和问题,同时考虑到多次重复分析的检验。当存在多个结局时,每个结局可以根据其严重程度给予相应的权重。本文介绍了一种用于多个加权二项结局的精确序贯分析程序;该分析纳入了药物的综合获益和安全性特征。它适用于各种连续、分组或混合组-连续序贯分析的α支出函数。二项概率可以随时间变化,并且不需要事先知道。新方法已在免费的 R 序贯软件包中实现,用于单尾和双尾序贯分析。本文提供了一个例子,检验了开始使用非甾体抗炎药的患者的心肌梗死和大出血事件。